NO20010893D0 - Stabilisert farmasøytisk materiale i lyofilisert form - Google Patents

Stabilisert farmasøytisk materiale i lyofilisert form

Info

Publication number
NO20010893D0
NO20010893D0 NO20010893A NO20010893A NO20010893D0 NO 20010893 D0 NO20010893 D0 NO 20010893D0 NO 20010893 A NO20010893 A NO 20010893A NO 20010893 A NO20010893 A NO 20010893A NO 20010893 D0 NO20010893 D0 NO 20010893D0
Authority
NO
Norway
Prior art keywords
lyophilized form
pharmaceutical material
stabilized pharmaceutical
stabilized
lyophilized
Prior art date
Application number
NO20010893A
Other languages
English (en)
Other versions
NO330353B1 (no
NO20010893L (no
Inventor
Seiji Sawai
Akihiro Kasai
Kazumi Otomo
Original Assignee
Fujisawa Pharmaceutical Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=16210881&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=NO20010893(D0) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Fujisawa Pharmaceutical Co filed Critical Fujisawa Pharmaceutical Co
Publication of NO20010893D0 publication Critical patent/NO20010893D0/no
Publication of NO20010893L publication Critical patent/NO20010893L/no
Publication of NO330353B1 publication Critical patent/NO330353B1/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/12—Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • A61P33/08—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis for Pneumocystis carinii
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Inorganic Chemistry (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Dermatology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Pulmonology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
NO20010893A 1999-07-01 2001-02-22 Stabilisert farmasoytisk materiale i lyofilisert form NO330353B1 (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP18771399 1999-07-01
PCT/JP2000/004381 WO2001002002A1 (en) 1999-07-01 2000-06-29 Stabilized pharmaceutical composition in lyophilized form

Publications (3)

Publication Number Publication Date
NO20010893D0 true NO20010893D0 (no) 2001-02-22
NO20010893L NO20010893L (no) 2001-04-24
NO330353B1 NO330353B1 (no) 2011-04-04

Family

ID=16210881

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20010893A NO330353B1 (no) 1999-07-01 2001-02-22 Stabilisert farmasoytisk materiale i lyofilisert form

Country Status (28)

Country Link
US (2) US6774104B1 (no)
EP (1) EP1107777B1 (no)
JP (2) JP3381722B2 (no)
KR (1) KR100454784B1 (no)
CN (2) CN100352495C (no)
AR (1) AR024634A1 (no)
AT (1) ATE280583T1 (no)
AU (1) AU752265B2 (no)
BR (2) BRPI0006823B8 (no)
CA (1) CA2341568C (no)
CZ (1) CZ295720B6 (no)
DE (1) DE60015279T2 (no)
ES (1) ES2225161T3 (no)
HK (2) HK1040057B (no)
HU (1) HU229089B1 (no)
ID (1) ID29468A (no)
IL (2) IL141455A0 (no)
MX (1) MXPA01000601A (no)
NO (1) NO330353B1 (no)
NZ (1) NZ510290A (no)
OA (1) OA11601A (no)
PL (1) PL200141B1 (no)
PT (1) PT1107777E (no)
RU (1) RU2251411C2 (no)
TR (1) TR200100609T1 (no)
TW (1) TWI233805B (no)
WO (1) WO2001002002A1 (no)
ZA (1) ZA200101589B (no)

Families Citing this family (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI233805B (en) * 1999-07-01 2005-06-11 Fujisawa Pharmaceutical Co Stabilized pharmaceutical composition in lyophilized form as antifungal agent
ITMI20021040A1 (it) * 2002-05-16 2003-11-17 Novuspharma Spa Composizioni farmaceutiche iniettabili di un derivato antracenedionico ad attivita' antitumorale
EP1525884B1 (en) 2002-07-31 2011-10-12 Senju Pharmaceutical Co., Ltd. Aqueous liquid preparations and light-stabilized aqueous liquid preparations
US8877168B1 (en) 2002-07-31 2014-11-04 Senju Pharmaceuticals Co., Ltd. Aqueous liquid preparations and light-stabilized aqueous liquid preparations
US7119061B2 (en) * 2002-11-18 2006-10-10 Vicuron Pharmaceuticals, Inc. Dalbavancin compositions for treatment of bacterial infections
EP1565201B1 (en) * 2002-11-18 2018-10-31 Vicuron Pharmaceuticals, Inc. Methods of administering dalbavancin for treatment of bacterial infections
US20060074014A1 (en) * 2002-11-18 2006-04-06 Vicuron Pharmaceuticals Inc. Dalbavancin compositions for treatment of bacterial infections
CA2558191C (en) * 2004-03-04 2011-01-04 Eisai R&D Management Co., Ltd. Composition containing benzamidine derivative and method for stabilizing benzamidine derivative
US7514450B2 (en) * 2004-05-19 2009-04-07 Neurosearch A/S Azabicyclic aryl derivatives
EP1814591A4 (en) * 2004-11-22 2009-04-22 Anadis Ltd BIOACTIVE PREPARATIONS
KR101307999B1 (ko) * 2004-12-01 2013-09-12 니폰 조키 세야쿠 가부시키가이샤 건조물 및 그 제조방법
US8173385B2 (en) * 2005-07-20 2012-05-08 Kyowa Medex Co., Ltd. Method for stabilization of peptides in a biological sample
CN1962852B (zh) * 2006-11-27 2011-11-09 西北农林科技大学 红景天多糖在制备抗冻剂中的新用途及其产品和制备方法
CN102614491B (zh) * 2011-01-31 2014-04-16 上海天伟生物制药有限公司 一种含有棘白菌素类抗真菌剂米卡芬净的药用组合物及其制备方法和用途
CN102614492B (zh) * 2011-01-31 2013-12-11 上海天伟生物制药有限公司 一种含有棘白菌素类抗真菌剂米卡芬净的液体药用组合物
GEP20186852B (en) * 2012-05-22 2018-05-25 Uk Limited Paion Compositions comprising short-acting benzodiazepines
US9872906B2 (en) 2013-03-15 2018-01-23 Merck Sharp & Dohme Corp. Ceftolozane antibiotic compositions
US20140274997A1 (en) 2013-03-15 2014-09-18 Cubist Pharmaceuticals, Inc. Cephalosporin pharmaceutical compositions
US20140274989A1 (en) 2013-03-15 2014-09-18 Cubist Pharmaceuticals, Inc. Manufacturing beta-lactam combination products
CN103330933B (zh) * 2013-04-26 2015-08-05 江苏豪森药业股份有限公司 含有米卡芬净或其盐的药物组合物
CN103330932B (zh) * 2013-04-26 2015-12-23 江苏豪森药业股份有限公司 一种米卡芬净或其盐的药物组合物
SG11201510003VA (en) * 2013-06-05 2016-01-28 Univ British Columbia Anti-fibrogenic compounds, methods and uses thereof
ES2800603T3 (es) 2013-09-09 2021-01-04 Merck Sharp & Dohme Tratamiento de infecciones con ceftolozano/tazobactam en sujetos con insuficiencia renal
US8906898B1 (en) 2013-09-27 2014-12-09 Calixa Therapeutics, Inc. Solid forms of ceftolozane
KR101611349B1 (ko) 2014-04-14 2016-04-12 신우철 안정성이 개선된 밀크씨슬 엑스의 제형
EP3150621A4 (en) * 2014-05-29 2017-12-27 Shanghai Techwell Biopharmaceutical Co., Ltd Composition of cyclic peptide compound, preparation method for same, and uses thereof
ES2821826T3 (es) * 2014-12-05 2021-04-27 Meiji Seika Pharma Co Ltd Método para producir cristales de derivado de diazabiciclooctano y preparación liofilizada estable
PL3240529T3 (pl) * 2014-12-31 2022-05-02 Galenicum Health S.L.U. Stabilne kompozycje farmaceutyczne zawierające mykafunginę
EP3058958B1 (en) 2015-02-23 2018-09-19 Selectchemie AG Anidulafungin composition
US20180169180A1 (en) 2016-12-16 2018-06-21 Baxter International Inc. Micafungin compositions
US11185527B2 (en) 2017-06-26 2021-11-30 Wayne State University Methods and compositions relating to steroid hormone receptor-dependent cancers
RU2666148C1 (ru) * 2017-10-05 2018-09-06 Общество с ограниченной ответственностью "Новые Антибиотики" Способ получения водорастворимой лиофилизированной формы соли бис(2-тио-4,6-диоксо-1,2,3,4,5,6-гексагидропиримидин-5-ил)-(4-нитрофенил)метана
EP3485873A1 (en) 2017-11-17 2019-05-22 Cadila Healthcare Limited Stable pharmaceutical injectable compositions of micafungin

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH03193735A (ja) 1989-12-22 1991-08-23 Shionogi & Co Ltd グリコペプチド系抗生物質の安定化組成物
JPH03240727A (ja) 1990-02-15 1991-10-28 Toyo Jozo Co Ltd ニューモシスチス・カリニ肺炎治療剤
IE990233A1 (en) * 1990-06-18 2000-11-15 Fujisawa Pharmaceutical Co New Polypeptide Compound and a Process for Preparation thereof
JP3193735B2 (ja) 1991-07-24 2001-07-30 株式会社リコー カラー画像形成装置の搬送装置
JPH0651641A (ja) 1992-07-30 1994-02-25 Olympus Optical Co Ltd 湿式現像装置
JPH06172204A (ja) * 1992-12-09 1994-06-21 Asahi Chem Ind Co Ltd アクレアシン類含有リポソーム製剤およびその製造法
JP3240727B2 (ja) 1993-02-25 2001-12-25 ソニー株式会社 偏平型陰極線管の画像歪補正装置
IL109615A (en) * 1993-05-17 2000-12-06 Fujisawa Pharmaceutical Co Cyclic polypeptide derivatives processes for the preparation thereof and pharmaceutical compositions containing the same
KR100353303B1 (ko) 1994-10-07 2003-01-15 후지사와 야꾸힝 고교 가부시키가이샤 항균활성을갖는고리형헥사펩티드
GB9512854D0 (en) * 1995-06-23 1995-08-23 Wellcome Found Novel formulation
KR100545506B1 (ko) * 1996-03-08 2006-10-04 아스테라스 세이야쿠 가부시키가이샤 환상 리포펩티드 물질의 탈아실화 방법
AR006598A1 (es) * 1996-04-19 1999-09-08 Merck Sharp & Dohme "composiciones anti-fungosas, su uso en la manufactura de medicamentos y un procedimiento para su preparación"
JPH09301997A (ja) 1996-05-17 1997-11-25 Yamanouchi Pharmaceut Co Ltd 新規環状ペプチド系化合物
AUPO371596A0 (en) * 1996-11-19 1996-12-12 Fujisawa Pharmaceutical Co., Ltd. New compound
FR2755857B1 (fr) * 1996-11-19 1998-12-24 Rhone Poulenc Rorer Sa Compositions pharmaceutiques stabilisees, a base de quinupristine et de dalfopristine et leur preparation
AUPO381496A0 (en) * 1996-11-25 1996-12-19 Fujisawa Pharmaceutical Co., Ltd. New compound
JPH10279498A (ja) * 1997-04-07 1998-10-20 Nippon Shinyaku Co Ltd 慢性関節リウマチ治療剤
JP3544847B2 (ja) * 1998-01-16 2004-07-21 三菱電機株式会社 光学的情報再生方法および装置
EP1156784A1 (en) * 1999-03-03 2001-11-28 Eli Lilly And Company Processes for making pharmaceutical oral ecb formulations and compositions
DK1582204T3 (da) * 1999-03-03 2013-11-04 Lilly Co Eli Echinocandin-farmaceutiske formuleringer, der indeholder miceldannende overfladeaktive stoffer
TWI233805B (en) * 1999-07-01 2005-06-11 Fujisawa Pharmaceutical Co Stabilized pharmaceutical composition in lyophilized form as antifungal agent

Also Published As

Publication number Publication date
WO2001002002A1 (en) 2001-01-11
CA2341568C (en) 2011-10-25
CZ20011186A3 (cs) 2001-09-12
HK1040057B (zh) 2005-08-05
DE60015279D1 (de) 2004-12-02
JP3381722B2 (ja) 2003-03-04
TR200100609T1 (tr) 2001-07-23
OA11601A (en) 2004-07-30
US20040157769A1 (en) 2004-08-12
US7112565B2 (en) 2006-09-26
KR100454784B1 (ko) 2004-11-05
NO330353B1 (no) 2011-04-04
PL200141B1 (pl) 2008-12-31
HK1080724A1 (en) 2006-05-04
CA2341568A1 (en) 2001-01-11
DE60015279T2 (de) 2005-05-25
IL141455A0 (en) 2002-03-10
JP2002363097A (ja) 2002-12-18
NZ510290A (en) 2003-07-25
PT1107777E (pt) 2005-01-31
CN1179748C (zh) 2004-12-15
AU752265B2 (en) 2002-09-12
EP1107777B1 (en) 2004-10-27
TWI233805B (en) 2005-06-11
AR024634A1 (es) 2002-10-16
AU5572200A (en) 2001-01-22
CN100352495C (zh) 2007-12-05
ES2225161T3 (es) 2005-03-16
PL346297A1 (en) 2002-01-28
MXPA01000601A (es) 2002-04-08
BRPI0006823B1 (pt) 2020-01-07
JP4691866B2 (ja) 2011-06-01
ZA200101589B (en) 2002-09-02
RU2251411C2 (ru) 2005-05-10
NO20010893L (no) 2001-04-24
JP2003503462A (ja) 2003-01-28
ATE280583T1 (de) 2004-11-15
HUP0103740A2 (hu) 2002-02-28
US6774104B1 (en) 2004-08-10
CZ295720B6 (cs) 2005-10-12
KR20010072903A (ko) 2001-07-31
CN1636591A (zh) 2005-07-13
HU229089B1 (en) 2013-07-29
ID29468A (id) 2001-08-30
CN1315865A (zh) 2001-10-03
EP1107777A1 (en) 2001-06-20
IL141455A (en) 2006-12-31
BR0006823A (pt) 2001-06-05
HUP0103740A3 (en) 2002-08-28
BRPI0006823B8 (pt) 2021-05-25
HK1040057A1 (en) 2002-05-24

Similar Documents

Publication Publication Date Title
NO20010893D0 (no) Stabilisert farmasøytisk materiale i lyofilisert form
DE60023165D1 (de) Flash-gesponnenes flächiges material
DE60011720D1 (de) Verbindungsmaterial
PT1157023E (pt) Epotilonas modificadas em c-21
DE60003664D1 (de) Filtermaterial
DE60006739D1 (de) Dekoratives Material
ATE236898T1 (de) S-omeprazol in festform
DE69822656D1 (de) Formmasse
DE60020074D1 (de) Hilfsstoff-zusammensetzung
ID29262A (id) Komposisi farmasi
ID27201A (id) Komposisi farmasi
ID27150A (id) Sediaan levotiroksin bahan farmasi
DK1246782T3 (da) Ekstruderbart cementholdigt materiale
ATE402913T1 (de) Kompositwerkstoff
IT1313432B1 (it) Indumento in materiale composito
DE69914948D1 (de) Polyesterformmasse
ID26215A (id) Komposisi farmasi
GB0029783D0 (en) Arrangement in moving crusher
IT248325Y1 (it) Trinciatrice
DK1189600T3 (da) GRF-holdige lyofiliserede farmaceutiske præparater
DE29900284U1 (de) Leuchtelemente in Betonsteinprodukten
DE29719171U1 (de) Matratze in Vollmaterial-Ausbildung
PT1204566E (pt) Transportador de artigos desmontavel e sua estrutura
IT1311788B1 (it) Pannello in materiale ligneo per mobili rivestito in materialetermodeformabile.
DK1107777T3 (da) Stabiliseret farmaceutisk præparat i lyofiliseret form

Legal Events

Date Code Title Description
CREP Change of representative

Representative=s name: PLOUGMANN 6 VINGTOFT POSTBOKS 1003 SENTRUM OSLO, 0

MK1K Patent expired